LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

August 02, 2023 | Last Trade: US$7.83 0.00 0.00

LOS ANGELES / Aug 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss second quarter 2023 results and provide a general business update on Wednesday, August 9, at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior. The dial-in information is as follows:

Date: Wednesday, August 9, 2023
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-330-2446
Conference ID: 4126168
Webcast link: ChromaDex Second Quarter 2023 Earnings Conference Call

The conference call will be broadcast live and will be available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available from 7:30 p.m. ET on Wednesday, August 9, 2023, to 11:59 p.m. ET on Wednesday, August 16, 2023.

Toll-free replay number: 1-800-770-2030
Replay ID: 4126168

About ChromaDex

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page